Ken Griffin Puma Biotechnology, Inc. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 46,700 shares of PBYI stock, worth $227,429. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,700

Previous 32,700 42.81%

Holding current value

$227,429

Previous $96,000 66.67%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$2.74 - $3.72 $1.39 Million - $1.89 Million	507,818 New	507,818 $1.74 Million
Q4 2024 Feb 14, 2025	BUY	$2.42 - $3.39 $369,137 - $517,097	152,536 Added 2214.2%	159,425 $486,000
Q3 2024 Nov 14, 2024	SELL	$2.25 - $4.03 $10,669 - $19,110	-4,742 Reduced 40.77%	6,889 $17,000
Q2 2024 Aug 14, 2024	BUY	$2.92 - $5.83 $33,962 - $67,808	11,631 New	11,631 $37,000
Q4 2023 Feb 14, 2024	SELL	$2.23 - $4.49 $130,046 - $261,843	-58,317 Reduced 32.38%	121,796 $527,000
Q3 2023 Nov 14, 2023	SELL	$2.63 - $4.09 $103,419 - $160,831	-39,323 Reduced 17.92%	180,113 $473,000
Q2 2023 Aug 14, 2023	SELL	$2.6 - $3.58 $44,041 - $60,641	-16,939 Reduced 7.17%	219,436 $774,000
Q1 2023 May 15, 2023	BUY	$2.21 - $4.82 $189,657 - $413,642	85,818 Added 57.0%	236,375 $730,000
Q4 2022 Feb 14, 2023	SELL	$2.12 - $5.08 $125,944 - $301,792	-59,408 Reduced 28.29%	150,557 $636,000
Q3 2022 Nov 14, 2022	SELL	$2.27 - $3.84 $203,192 - $343,726	-89,512 Reduced 29.89%	209,965 $497,000
Q2 2022 Aug 15, 2022	BUY	$1.64 - $3.3 $356,285 - $716,915	217,247 Added 264.19%	299,477 $853,000
Q1 2022 May 16, 2022	SELL	$2.13 - $3.24 $783 - $1,192	-368 Reduced 0.45%	82,230 $237,000
Q4 2021 Feb 14, 2022	SELL	$2.85 - $6.58 $334,333 - $771,899	-117,310 Reduced 58.68%	82,598 $251,000
Q3 2021 Nov 15, 2021	BUY	$6.63 - $9.39 $20,354 - $28,827	3,070 Added 1.56%	199,908 $1.4 Million
Q2 2021 Aug 16, 2021	BUY	$8.98 - $11.6 $108,029 - $139,548	12,030 Added 6.51%	196,838 $1.81 Million
Q1 2021 May 17, 2021	SELL	$9.38 - $13.63 $317,569 - $461,457	-33,856 Reduced 15.48%	184,808 $1.8 Million
Q4 2020 Feb 16, 2021	SELL	$7.78 - $12.13 $1.52 Million - $2.37 Million	-195,007 Reduced 47.14%	218,664 $2.24 Million
Q3 2020 Nov 16, 2020	BUY	$9.5 - $11.14 $3.01 Million - $3.53 Million	317,066 Added 328.21%	413,671 $4.17 Million
Q2 2020 Aug 14, 2020	SELL	$7.01 - $13.24 $1.03 Million - $1.95 Million	-147,463 Reduced 60.42%	96,605 $1.01 Million
Q1 2020 May 15, 2020	SELL	$6.28 - $14.57 $1.88 Million - $4.36 Million	-299,008 Reduced 55.06%	244,068 $2.06 Million
Q4 2019 Feb 14, 2020	BUY	$6.5 - $10.73 $549,744 - $907,500	84,576 Added 18.45%	543,076 $4.75 Million
Q3 2019 Nov 14, 2019	SELL	$8.75 - $12.85 $5.85 Million - $8.59 Million	-668,343 Reduced 59.31%	458,500 $4.94 Million
Q2 2019 Aug 14, 2019	BUY	$12.3 - $35.76 $7.75 Million - $22.5 Million	630,126 Added 126.86%	1,126,843 $14.3 Million
Q1 2019 May 15, 2019	BUY	$20.77 - $42.37 $3.81 Million - $7.78 Million	183,600 Added 58.64%	496,717 $0
Q4 2018 Feb 14, 2019	SELL	$20.07 - $46.7 $16.3 Million - $37.9 Million	-811,314 Reduced 72.15%	313,117 $6.37 Million
Q3 2018 Nov 13, 2018	BUY	$41.2 - $59.85 $13 Million - $18.9 Million	316,423 Added 39.16%	1,124,431 $0
Q2 2018 Aug 10, 2018	BUY	$48.3 - $68.25 $38.3 Million - $54.2 Million	793,652 Added 5528.36%	808,008 $0
Q1 2018 May 11, 2018	SELL	$59.7 - $99.25 $49.1 Million - $81.6 Million	-822,569 Reduced 98.28%	14,356 $977,000
Q4 2017 Feb 09, 2018	SELL	$93.85 - $132.45 $19.6 Million - $27.7 Million	-209,155 Reduced 19.99%	836,925 $82.7 Million
Q3 2017 Nov 09, 2017	BUY	$72.0 - $119.75 $75.3 Million - $125 Million	1,046,080	1,046,080 $125 Million

Others Institutions Holding PBYI

# of Institutions

124

Shares Held

33.3M

Call Options Held

68.2K

Put Options Held

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $222M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account